

## VOQUEZNA - (EQ 10MG BASE,EQ 20MG BASE ; Tablet)

<b>Generic Name</b>	VONOPRAZAN FUMARATE	<b>Innovator</b>	PHATHOM
<b>Dosage</b>	EQ 10MG BASE,EQ 20MG BASE ; Tablet	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	None	<b>Known Para IV Filers</b>	None
<b>Other ANDA developers</b>	More Than 5	<b>Tentative Approvals</b>	None
<b>Final Approvals</b>	None	<b>Generic Launches</b>	None
<b>Indication</b>	VOQUEZNA is a potassium-competitive acid blocker indicated: For healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults. To maintain healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults. In combination with amoxicillin and clarithromycin for the treatment of Helicobacter pylori (H. pylori) infection in adults. In combination with amoxicillin for the treatment of H. pylori infection in adults.		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.